在埃尔德海姆-切斯特病的多焦点硬化病变成功地用tocilizumab治疗
Henk-Jan Boiten1, E J Libourel1
1Department of Internal Medicine - Hematology, Franciscus Gasthuis and Vlietland, Schiedam, The Netherlands.
Immunotherapy
|September 17, 2025
概括
埃尔德海姆-切斯特病 (ECD) 是一种罕见的疾病,导致骨疼痛. 这项研究表明,tocilizumab是一种IL-6受体抗体,是一种有前途的治疗方法,用于只涉及骨的ECD.
科学领域:
- 在瘤学瘤学.
- 类风湿病学 类风湿病学
- 病理学 病理学 病理学
背景情况:
- 埃尔德海姆 - 切斯特病 (ECD) 是一种罕见的非朗格汉斯细胞囊炎.
- 电脑脊髓炎通常涉及多个器官,但可能会发生孤立的骨参与.
- 由于非特异性症状和各种表现,诊断可能具有挑战性.
研究的目的:
- 报告埃尔德海姆 - 切斯特病 (ECD) 病例,其中骨完全受到影响.
- 评估托西利祖马布在治疗这种罕见疾病中的疗效.
- 突出托西利祖马布作为有限器官参与的潜在治疗选择.
主要方法:
- 一名58岁的妇女出现了严重的骨疼痛和升高的炎症标志物.
- 诊断工作包括骨扫描,PET/CT和骨活检.
- 组织病理学揭示了CD68和XIIIa因子阳性囊细胞,排除了其他瘤.
主要成果:
- 图像检测显示,长骨和半径骨中的硬化骨损伤.
- 活检证实了埃尔德海姆-切斯特病 (ECD),没有其他器官参与.
- 以IL-6受体抗体托西利祖马布 (tocilizumab) 进行每周治疗,导致症状成功消失.
结论:
- 埃尔德海姆-切斯特病 (ECD) 可以出现孤立的骨损伤.
- 托西利祖马布在这种骨 ECD 病例中表现出显著的疗效.
- 用托西利祖马布阻断IL-6是一种有前途的治疗策略,用于有限器官参与的埃尔德海姆-切斯特病.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
T Cell Types and Functions
2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K


